A Randomized Clinical Trial to Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones

Inclusion Criteria (Participants must meet all of the following criteria to be eligible) * Age: ≥18 years old. * Diagnosis: Patients undergoing ureteral stenting post-ureteroscopy for uric acid kidney stones. * Urinary pH: ≤5.5 at baseline (acidic urine). * Willingness to Participate: Patients who provide informed consent to participate in the study. Exclusion Criteria (Participants will be excluded if they meet any of the following criteria) Renal Function: Patients with significantly impaired kidney function (elevated creatinine beyond normal limits). Infections: History of febrile urinary tract infection (UTI) at the time of enrollment. Metabolic Disorders: Chronic kidney disease (CKD) Stage 3 or higher. History of hyperkalemia. Pregnancy: Pregnant or breastfeeding women. Residual Stones: Patients with residual stone burden after ureteroscopy that may confound outcomes. Medication Interference: Patients on medications that significantly alter urinary pH (e.g., sodium bicarbonate, acetazolamide) or those contraindicated with potassium citrate. Other Severe Comorbidities: Any condition that, in the investigator's judgment, would interfere with study participation or pose excessive risk.